Juice Plus Inflammaging and Cardiovascular Disease Prevention Study
Launched by GREEN BEAT · Jun 28, 2019
Trial Information
Current as of June 10, 2025
Terminated
Keywords
ClinConnect Summary
Inflammation is a central component of innate (non-specific) immunity. The termination of inflammation is an active process involving cytokines and anti-inflammatory mediators like lipids and micronutrients. Inflammation acts as both, 'friend and foe'; it is an essential component of immunosurveillance and host defense, but a chronic low-grade inflammatory state is a pathological feature of a wide range of chronic conditions, such as the metabolic syndrome or cardiovascular diseases (CVD). In addition, low-grade inflammation and oxidative stress are often associated with increased body fat ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 90 male and female subjects
- • age: 50 - 80 years
- • post- or peri-menopausal
- • Smokers and non-smokers
- • BMI 25 to 40 kg/m2
- • Dietary Inflammatory Index, DII: 0 to +10
- • Fruit and vegetable intake \<4 servings/d
- • Adherence to a 6-week "wash-out" period
- • Since the intervals between blood drawings are long (6 months), a temporary intake (e.g for a few days, one or two weeks) of some excluded drugs and food supplements does not necessarily mean exclusion from the study
- Exclusion Criteria:
- • Age \<50 and \>79.9 years
- • Dietary Inflammatory Index, DII: - 0.1 to -10
- • Subjects with any kind of food allergy or histamine intolerance
- • Aversion to stop the intake of nutritional supplements and food, that could interfere with the study outcome
- • Food supplements, functional foods and dietetic products with anti-inflammatory or redox-biological relevance like omega-3 fatty acids, plant/herbal extracts/concentrates, vitamin- and mineral supplements
- • Fruit and vegetable intake \>3 servings per day
- • Hypertension, starting with grade 2 according to the classification of the European Society of Hypertension: systolic blood pressure \> 160 mmHg, diastolic blood pressure \>100 mmHg
- • Medication: any anti-inflammatory medication and medication with relevant antioxidant properties, blood pressure lowering medication, psychotropic drugs, immunosuppressives, cytostatics, anticoagulants, contraceptives, diuretics, pain medication
- • Clinically relevant infectious disease
- • Diabetes mellitus type I and type II
- • Auto-immuno diseases
- • Any stents and Coronary artery diseases (CAD)
- • Cancer patients
- • Pregnancy
About Green Beat
Green Beat is an innovative clinical trial sponsor committed to advancing healthcare through groundbreaking research and development. With a focus on sustainable and environmentally conscious practices, Green Beat specializes in facilitating clinical trials that prioritize patient safety and efficacy while minimizing ecological impact. The organization collaborates with a diverse range of stakeholders, including pharmaceutical companies, research institutions, and healthcare providers, to drive forward the development of novel therapies and treatment modalities. By leveraging cutting-edge technology and a patient-centered approach, Green Beat aims to contribute to the advancement of medical science and improve health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Graz, , Austria
Graz, Styria, Austria
Patients applied
Trial Officials
Manfred Lamprecht, PhD
Principal Investigator
Medical University of Graz
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials